The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 30, 2024
Filed:
Aug. 25, 2021
Applicant:
Celgene Corporation, Summit, NJ (US);
Inventors:
Ho-Wah Hui, Basking Ridge, NJ (US);
Yu Pu, East Hanover, NJ (US);
Assignee:
Celgene Corporation, Summit, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/454 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 39/395 (2006.01); A61K 47/12 (2006.01); A61K 47/40 (2006.01); C07K 16/00 (2006.01); A61K 47/18 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 9/0019 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 39/395 (2013.01); A61K 47/12 (2013.01); A61K 47/40 (2013.01); C07K 16/00 (2013.01); A61K 47/18 (2013.01); A61K 2039/505 (2013.01);
Abstract
Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.